AstraZeneca after £5m investment to develop UK R&D site
Hannah Blake
pharmaphorum
Global drugmaker, AstraZeneca, has successfully applied for a £5 million investment from the UK Department for Business, Innovation and Skills’ Regional Growth Fund. The investment will allow AstraZeneca to further explore the potential of developing a BioScience cluster on its Alderley Park R&,d site.
The venture will create a unique hub for pharmaceutical innovation and biotech enterprise in the North West, representing a positive example of progress for the UK’s life sciences sector.
“This initiative reflects the changing face of pharmaceutical R&,D and our focus on collaboration to access and develop the best science and technology. Alderley Park is a site of critical importance to our global R&,D organisation. By combining our capabilities with those of our partners and other enterprises, we aim to create a hub of scientific innovation with the potential to discover the medicines that people will need in years to come.”
Martin Mackay, President of R&,D at AstraZeneca.
AZ will now work, over the next three to six months, on the due diligence required to finalise the proposed plans.
Related news:
Companies boosted by Regional Growth Fund awards (Manchester Business Awards)
Reference links:
